Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $1,100.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price boosted by Guggenheim from $1,030.00 to $1,100.00 in a research report released on Monday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

REGN has been the topic of several other research reports. Zacks Research raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 28th. Royal Bank Of Canada increased their target price on shares of Regeneron Pharmaceuticals from $737.00 to $810.00 and gave the stock a “sector perform” rating in a report on Thursday, October 8th. Canaccord Genuity Group raised their price target on Regeneron Pharmaceuticals from $875.00 to $922.00 and gave the company a “buy” rating in a research note on Wednesday, October 28th. Piper Sandler boosted their price objective on shares of Regeneron Pharmaceuticals from $854.00 to $865.00 and gave the stock an “overweight” rating in a research note on Monday, October 19th. Finally, Bank of America boosted their target price on Regeneron Pharmaceuticals from $908.00 to $1,030.00 and gave the stock a “buy” rating in a report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $898.97.

Regeneron Pharmaceuticals Trading Down 4.4%

REGN opened at $930.67 on Monday. The firm has a 50 day simple moving average of $800.69 and a 200 day simple moving average of $741.11. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.35 and a quick ratio of 3.66. Regeneron Pharmaceuticals has a fifty-two week low of $591.52 and a fifty-two week high of $991.73. The company has a market cap of $95.82 billion, a price-to-earnings ratio of 20.38, a price-to-earnings-growth ratio of 1.45 and a beta of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, beating analysts’ consensus estimates of $16.51 by $3.56. The company had revenue of $5.12 billion for the quarter, compared to the consensus estimate of $4.58 billion. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The firm’s quarterly revenue was up 36.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $11.83 EPS. On average, sell-side analysts anticipate that Regeneron Pharmaceuticals will post 51.64 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Friday, November 20th will be paid a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date is Friday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.30%.

Insiders Place Their Bets

In other news, EVP Marion Mccourt sold 1,215 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $1,032,750.00. Following the sale, the executive vice president directly owned 13,134 shares in the company, valued at approximately $11,163,900. This trade represents a 8.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $640,000.00. Following the completion of the transaction, the director owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. This trade represents a 31.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 20,789 shares of company stock valued at $18,766,698 over the last three months. 6.97% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. purchased a new position in shares of Regeneron Pharmaceuticals in the second quarter worth about $5,682,636,000. Legal & General Group Plc purchased a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at approximately $473,872,000. Bank of New York Mellon Corp purchased a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at approximately $472,950,000. Deutsche Bank AG bought a new position in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $323,249,000. Finally, Man Group plc bought a new position in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $272,460,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Bank of America added REGN to its Value 10 list, a favorable signal about the stock’s value appeal. BofA adds REGN to Value 10 list
• Positive Sentiment: Recent analyst coverage points to higher price targets and expectations for appreciation. Separately, Zacks said solid earnings-estimate revisions could help the shares continue gaining. These views follow Regeneron’s recent quarterly results, which beat consensus on earnings and revenue. RBC raises Regeneron price target Zacks on earnings estimate revisions
• Negative Sentiment: Recent disclosures show EVP Joseph Larosa sold 4,466 shares and director Christine Poon sold 7,830 shares on November 2; Poon’s sale cut her direct holding by 60%. Director Kathryn Guarini also sold 400 shares under a pre-arranged trading plan. The larger transactions could raise concerns about insider sentiment, though sales alone do not indicate a change in the company’s business outlook. Larosa sale filing Poon sale filing Guarini sale filing

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.